[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628885":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":48,"id":58,"slug":59,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":72,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":79,"overallStatus":31,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Neuromed IRCCS","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"PD patients",null,"PD participants will be assessed for disease progression, including Hoehn and Yahr stage, MDS-UPDRS Part III, MoCA test, non-motor symptoms, therapy, occurrence of LID, and sleep disorders. Participants will undergo brain magnetic resonance imaging (MRI). Participants will undergo peripheral blood sampling for the isolation of DNA, plasma, serum, and PBMCs, as well as for the generation of hiPSCs. The DNA of each participant will be analyzed by whole-exome sequencing to identify variants in candidate PD genes. DNA will also be analyzed to assess the epigenetic profile. Plasma and serum samples will be analyzed to evaluate metabolomic, lipidomic, and proteomic profiles.",{"label":13,"type":10,"description":14,"interventionNames":10},"AD patients","AD Partecipants will be assessed for disease progression: - assessment of cognitive disorders (MMSE, MOCA test, clock test); - assessment of language disorders; - current drug therapy (and possible start date of treatment); - date of onset of cognitive disorders; - acquisition and assessment of imaging data where present (MRI, CT, PET). Participants will undergo peripheral blood sampling for the isolation of DNA, plasma, serum. The DNA of each participant will be analyzed by whole-exome sequencing to identify variants in candidate AD genes. DNA will also be analyzed to assess the epigenetic profile. Plasma and serum samples will be analyzed to evaluate metabolomic, lipidomic, and proteomic profiles.",{"label":16,"type":10,"description":17,"interventionNames":10},"Type 2 Diabetes (T2D) patients","T2D Partecipants will be assessed for disease progression. Participants will undergo peripheral blood sampling for the isolation of DNA, plasma, serum. The DNA of each participant will be analyzed by whole-exome sequencing to identify variants in candidate T2D genes. DNA will also be analyzed to assess the epigenetic profile. Plasma and serum samples will be analyzed to evaluate metabolomic, lipidomic, and proteomic profiles.",[19],{"name":20,"affiliation":21,"role":22},"TERESA ESPOSITO, PhD","IRCCS INM Neuromed","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Teresa Esposito, PhD","CONTACT","+39 0865915249","teresa.esposito@igb.cnr.it",[30],{"facility":21,"status":31,"city":32,"state":10,"zip":33,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"RECRUITING","Pozzilli","86077","Italy","IT",{"type":37,"coordinates":38},"Point",[39,40],14.06252,41.51142,{"lat":40,"lon":39},[43],{"name":25,"role":26,"phone":44,"phoneExt":10,"email":28},"+30 0865915249",{"type":22,"investigatorFullName":46,"investigatorTitle":47,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Teresa Esposito","Researcher head of the CNR lab",[49,51,54,56],{"name":50,"class":6},"University of Campania Luigi Vanvitelli",{"name":52,"class":53},"Istituto di Genetica e Biofisica \"A. Buzzati Traverso\", CNR","UNKNOWN",{"name":55,"class":53},"Istituto degli Endotipi in Oncologia, Metabolismo e Immunologia \"G. Salvatore\" (IEOMI), CNR",{"name":57,"class":53},"Istituto di Calcolo e Reti ad Alte Prestazioni (ICAR), CNR","100628885","precision-medicine-and-neurodegenerative-diseases-advanced-systems-for-the-diagnosis-and-treatment-of-parkinsons-disease-and-alzheimers-disease-100628885",false,"NCT07467460","Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.","NEUROTECHNO: Precision Medicine and Neurodegenerative Diseases: Advanced Systems for the Diagnosis and Treatment of Parkinson's Disease and Alzheimer's Disease.","NEUROTECHNO","Inclusion Criteria:\n\n* -Inclusion Criteria:\n* Inclusion criteria for PD patients. For the IRCCS INM Neuromed, patients will be recruited from those affiliated with the Center for the Study and Treatment of Parkinson's Disease of the Neuromed Institute of Pozzilli.\n\nPresence of at least 2 of the 4 cardinal signs (tremor, rigidity, bradykinesia, asymmetric onset), one of which must be tremor or bradykinesia:\n\nAbsence of atypical symptoms such as: i) early postural instability, freezing episodes, cognitive decline, hallucinations, pathological involuntary movements, vertical gaze palsy; ii) confirmed causes of secondary parkinsonism (focal lesions, medications, toxic substances); Documented response to L-dopa or dopamine agonists (or lack of an adequate therapeutic trial with L-dopa or dopamine agonists).\n\n-Inclusion criteria forAD patients. For the University of Campania, patients will be selected at the Department of Advanced Medical and Surgical Sciences of the University of Campania \"L. Vanvitelli,\" located at Piazza Miraglia 2, Naples. The Department will establish a collaboration with the Alzheimer's day centers of ASL NA1 (Geriatric Facility \"Villa Walpole\" - Via Ponti Rossi, 118 - Naples, and Geriatric Facility \"Frullone\" - Via Comunale del Principe, 16\u002FA - Naples) to identify potential subjects for screening to verify the parameters required for recruitment. The Geriatrics and Internal Medicine Unit (UOC), AOU University of Campania, will also be involved.\n\nPatients with AD will be included following a diagnosis of probable Alzheimer's disease according to the McKhann criteria (2011), supported by positive biomarkers for amyloidopathy (amyloid PET or cerebrospinal fluid amyloid assay).\n\nExclusion Criteria:\n\n* Pre-existing psychiatric disorders;\n* Neurodegenerative neurological diseases such as multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, neuromuscular disorders, epilepsy;\n* Diagnosis of dementia.",true,"ALL","18 Years",{"count":70,"type":71},500,"ESTIMATED","24 Months","OBSERVATIONAL","In recent decades, advances in medicine have significantly improved both quality of life and life expectancy. However, these positive effects are also associated with a considerable increase in the prevalence of age-related diseases. Among these, Alzheimer's disease (AD), Parkinson's disease (PD), and type 2 diabetes (T2D) currently represent a major threat to human health. PD and AD are the most common neurodegenerative diseases in industrialized populations. In particular, AD accounts for 54% of all cases of dementia, with a prevalence of 4.4% among individuals over 65 years of age. PD has a prevalence of about 1% in people older than 60 years, reaching up to 4% in those over 80 years of age. AD and PD are highly disabling disorders with a slow but progressive course, caused by the degeneration and\u002For death of nerve cells. This results in impairments in the control of movement and balance, as in the case of PD, or in cognitive functioning, as in AD.\n\nTo date, neither effective treatments nor early diagnostic tools are available to address these conditions in the initial phase of neurodegeneration. Likewise, there are no tools capable of monitoring disease progression and improving patients' adaptation to therapy.\n\nMoreover, although the association between T2D and the risk of PD and\u002For AD has long been recognized, these conditions were historically considered unrelated. Recent evidence from clinical and epidemiological studies suggests the existence of shared pathophysiological mechanisms associated with insulin resistance and persistent inflammation in several metabolically relevant tissues, such as adipose tissue and the brain. However, the mechanisms that increase the risk of PD and\u002For AD in individuals with T2D remain poorly understood.\n\nThese data highlight how relevant these diseases are for the National Health System and demonstrate that they represent one of the most important priorities to be addressed, requiring substantial investments in both scientific research and early diagnostic strategies.\n\nTherefore, the present project proposal, which aims to develop new minimally invasive tools for the early prediction and monitoring of neurodegenerative diseases such as AD and PD, will help fill an important gap in the clinical and therapeutic management of these patients.",[76,77,78],"PARKINSON DISEASE (Disorder)","Alzheimer s Disease","Diabete Type 2",[80,81,82],"Identification of genetic and metabolic profiles associated with neurodegenerative diseases","Identification of epigenetic profiles associated with neurodegenerative diseases","Integration and analysis of omics and neuroimaging data","2026-03-09",{"date":85,"type":86},"2026-03-12","ACTUAL",{"date":88,"type":86},"2026-02-17",{"date":90,"type":71},"2028-09-30",{"name":5,"class":6},1]